1. Home
  2. INCR vs ELTX Comparison

INCR vs ELTX Comparison

Compare INCR & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intercure Ltd.

INCR

Intercure Ltd.

HOLD

Current Price

$5.27

Market Cap

58.6M

Sector

Health Care

ML Signal

HOLD

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

HOLD

Current Price

$2.05

Market Cap

63.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INCR
ELTX
Founded
1994
2011
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.6M
63.3M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
INCR
ELTX
Price
$5.27
$2.05
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$18.00
AVG Volume (30 Days)
28.5K
281.3K
Earning Date
05-01-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
39.29
EPS
N/A
N/A
Revenue
N/A
$2,301,000.00
Revenue This Year
$69.54
N/A
Revenue Next Year
$41.75
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.68
$2.17
52 Week High
$6.10
$16.00

Technical Indicators

Market Signals
Indicator
INCR
ELTX
Relative Strength Index (RSI) 75.60 22.25
Support Level $0.84 N/A
Resistance Level $6.10 $3.32
Average True Range (ATR) 0.29 0.13
MACD 0.00 -0.04
Stochastic Oscillator 83.80 4.33

Price Performance

Historical Comparison
INCR
ELTX

About INCR Intercure Ltd.

Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Share on Social Networks: